Clinical Trials Directory

Trials / Completed

CompletedNCT02026856

Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis

Status
Completed
Phase
Study type
Observational
Enrollment
4 (actual)
Sponsor
Pavol Jozef Safarik University · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study looked at parenteral administration of selenium to septic patients and subsequently monitored dynamic changes of selected activities of antioxidant enzymes and the development of clinical status.

Detailed description

Patients will be divided into two groups. Se-group who received selenium supplementation during hospitalization in the form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) (Selenase, Vivax; selenium hereinafter). The placebo group will receive continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy). Patients will be further divided into subgroups according to OI on the day of admission to ICU. The oxygenation index (OI) PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) ratio in patients will be calculated daily. The determination of biochemical and hematological parameters of blood samples will be as a part of the routine diagnostic methods. Data collection for the Se-AOX study will be performed at two-day intervals: T1 (1st-2nd day), T2 (3rd-4th day) and T3 (5th-6th day). Kinetic methods for estimating the activities of glutathione peroxidase (GPx, E.C. 1.11.1.9), glutathione reductase (GR, E.C.1.6.4.2) will be performed using a kit (Sigma-Aldrich, Germany) and that of superoxide dismutase (SOD, E.C. 1.15.1.1) by means of the SOD-Assay Kit-WST (Fluka, Japan) following the user manual provided.

Conditions

Interventions

TypeNameDescription
DRUGsodium selenite pentahydrate
OTHERplacebo - continuous saline NaCl 50 ml

Timeline

Start date
2013-12-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2014-01-03
Last updated
2017-04-10

Locations

1 site across 1 country: Slovakia

Source: ClinicalTrials.gov record NCT02026856. Inclusion in this directory is not an endorsement.